Tissue selectivity of antidiabetic agent nateglinide: Study on cardiovascular and β-cell K(ATP) channels

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1372-1379

  Hu, Smiling ^a   Wang, Shuya ^a   Dunning, Beth E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; NATEGLINIDE; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; REPAGLINIDE;

ANIMAL CELL; AORTA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; HEART MUSCLE CELL; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TISSUE SPECIFICITY;

ANIMALS; AORTA, THORACIC; CARBAMATES; CARDIOVASCULAR SYSTEM; CORONARY VESSELS; CYCLOHEXANES; GLYBURIDE; HEART; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MALE; MUSCLE, SMOOTH, VASCULAR; PHENYLALANINE; PIPERIDINES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 0032748867     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP, Boyd AE, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J and Nelson DA (1995) Cloning of the β-cell high affinity sulfonylurea receptor: A regulator of insulin secretion. Science (Wash DC) 268:423-425.
2. Akiyoshi M, Kakei M, Nakazaki M and Tanaka H (1995) A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 268:E185-E193.
3. Ashcroft FM, Harrison DE and Ashcroft SJH (1984) Glucose induces closure of single potassium channels in isolated pancreatic β-cells. Nature (Lond) 312:446-448.
4. Ashcroft FM and Rorsman P (1989) Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 54:87-143.
5. + channel blocking agent glibenclamide on ischemic and reperfusion arrhythmias. Eur J Pharmacol 326:147-156.
6. Cavero I, Djellas Y and Guillon JM (1995) Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther 9 (Suppl 2):245-255.
7. ATP channels. Diabetes 45: 1439-1445.
8. + channel. J Mol Cell Cardiol 29:175-182.
9. Cleveland JC, Meldrum DR, Cain BS, Banerjee A and Harken AH (1997b) Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited. Circulation 96:29-32.
10. + channels in pancreatic β-cells. Nature (Lond) 311:271-273.
11. + channels in cardiac muscle by the sulfonylurea drug glibenclamide. J Pharmacol Exp Ther 261:540-545.
12. Fuhlendorff J, Shymko R, Carr RD and Kofod H (1995) Characterization of the binding sites for the novel anti-hyperglycemic drug, repaglinide. Diabetes 47 (Suppl I):231A.
13. 3H]glibenclamide. Biochem Pharmacol 52:407-411.
14. + channel in rat pancreatic B-cells. Am J Physiol 257:C1119-C1127.
15. ATP channels. Diabetes 47:1412-1418.
16. Gromada J, Dissing S, Kofod H and Frakjaer-Jensen J (1995) Effects of the hypoglycemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologia 38:1025-1032.
17. Hamill OP, Marty A, Neher E, Sakmann B and Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfluegers Arch 391:85-100.
18. + channels in myocardial ischemia. Jpn Heart J 38:297-315.
19. + channels. Neuron 16:1011-1017.
20. Krause E, Englert H and Gogelein H (1995) Adenosine-triphosphate-dependent K currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim. Pfluegers Arch 429:625-635.
21. Leibowitz G and Cerasi E (1996) Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing? Diabetologia 39:503-524.
22. Malaisse WJ (1995A) Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res 27:263-266.
23. Nathan DM (1995) Inferences and implications: Do the DCCT results apply in NIDDM? Diabetes Care 18:251-257.
24. Nathan DM (1998) Some answers, more controversy, from UKPDS. Lancet 352:832-833.
25. Nelson MT and Quayle JM (1995) Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268:C799-C822.
26. Nichols CG and Lederer WJ (1991) Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 261:H1675-H1686.
27. Panten U, Burgfeld J and Goerke F (1989) Control of insulin secretion by sulphonylureas, meglitinide and diazoxide in relation to their binding to the sulphonylurea receptor in pancreatic islets. Biochem Pharm 38:1217-1229.
28. Pipeleers DG, Veld PA, Van de Windel M, Maes E, Schuit FC and Gepts W (1985) A new in vitro model for the study of pancreatic A and B cells. Endocrinology 117:806-816.
29. Pogasta G (1995) Potassium channels in the cardiovascular system. Diabetes Res Clin Pract 28 (Suppl 1):S91-S98.
30. + currents in smooth muscle cells from rabbit mesenteric artery. Am J Physiol 269:C1112-C1118.
31. Quayle JM, Nelson MT and Standen NB (1997) ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77:1165-1232.
32. Rajan AS, Aguilar-Bryan L, Nelson DA, Yaney GC, HSU WH, Kunze DL and Boyd AE (1990) Ion channels and insulin secretion. Diabetes Care 13:340-363.
33. Smits P and Thien T (1995) Cardiovascular effects of sulphonylurea derivatives. Diabetologia 38:116-121.
34. Sturgess NC, Kozlowski RZ, Carrington CA, Hales CN and Ashford MLJ (1988) Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol 85: 83-94.
35. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compares with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853.
36. University Group Diabetes Program (1976) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 25:1129-1153.
37. University Group Diabetes Program (1978) Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VII: Mortality and selected nonfatal events with insulin treatment. J Am Med Assoc 240:37-42.
38. + currents in smooth muscle cells of intact rat small arteries. Pfluegers Arch 427:110-120.
39. + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 274:C25-C37.
40. + currents in pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 337:225-230.